United States Radiotherapy Market

United States Radiotherapy Market Size:

United States radiotherapy market size is projected to exhibit a growth rate (CAGR) of 4.40% during 2024-2032. The market is propelled by the rising instances of cancer, the growing development of more sophisticated radiotherapy machines, significant innovations in radiotherapy technology, flourishing healthcare expenditures, and the widespread adoption of minimally invasive treatment options that offer precise targeting of tumors.

United States Radiotherapy Market Analysis:

• Major Market Drivers: The United States radiotherapy market share is influenced by the growing prevalence of cancer, which raises the demand for effective treatment options. Moreover, rapid technological advancements in radiotherapy, including enhanced imaging and precision targeting, improve treatment efficacy and safety, which, in turn, is favoring the market growth. Additionally, increasing healthcare expenditure and favorable reimbursement policies make advanced radiotherapy treatments more accessible to patients, further propelling market growth.
• Key Market Trends: Some of the key United States radiotherapy market trends involve the widespread adoption of advanced technologies like proton therapy and stereotactic radiosurgery, which provide higher precision in targeting tumors while minimizing damage to surrounding tissues. In line with this, the incorporation of artificial intelligence (AI) in radiotherapy planning and delivery is enhancing treatment accuracy and personalization. Furthermore, rising partnerships and collaborations among healthcare providers and technology firms are driving innovation and expanding access to cutting-edge radiotherapy solutions.
• Competitive Landscape: The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
• Challenges and Opportunities: Opportunities in the United States radiotherapy market include the growing focus on personalized medicine, which enhances treatment outcomes, and the expansion of telemedicine services, which increases access to radiotherapy in underserved areas. Challenges include the high cost of advanced radiotherapy equipment and treatments, which can limit accessibility, and the need for extensive training for healthcare professionals to effectively use cutting-edge technologies. Regulatory hurdles and ensuring consistent reimbursement policies also pose significant challenges.

United States Radiotherapy Market Trends:

Rising Incidences of Cancer

The increasing number of cancer cases in the United States is driving the radiotherapy market. According to the National Cancer Institute, in 2024, an estimated 2,001,140 new cancer cases will be diagnosed in the U.S., with 611,720 deaths expected. The most common cancers include breast, prostate, lung, colorectal, and melanoma. Prostate, lung, and colorectal cancers will account for 48% of diagnoses in men, while breast, lung, and colorectal cancers will account for 51% in women. The annual cancer incidence rate is 440.5 per 100,000 people, with a mortality rate of 146.0 per 100,000. Cancer mortality is higher in men (173.2) than women (126.4). Thus, the rising incidence and prevalence of cancer necessitate the development of advanced radiotherapy treatments, which are anticipated to further propel market growth in the region.

Rapid Technological Advancements

Rapid technological advancements are propelling the U.S. radiotherapy market by enhancing treatment precision and efficacy. According to a research article published in 2022 PubMed Central, these innovations have significantly improved radiotherapy's effectiveness, resulting in better cancer management, higher survival rates, and improved quality of life. Key developments include multileaf collimators, integration of imaging techniques like PET and CT, and advanced dose calculation algorithms and delivery methods, which have increased tumor dose distribution accuracy and reduced normal tissue toxicity. Techniques such as three-dimensional conformal radiotherapy (3DCRT), intensity-modulated radiotherapy (IMRT), stereotactic radiotherapy, image-guided radiotherapy (IGRT), and particle therapy have advanced treatment planning, accurate tumor delineation, and precise dose estimation for personalized treatments. These advancements encourage healthcare providers to adopt new technologies, driving market growth.

Growing Healthcare Expenditure and Reimbursement Policies

Higher healthcare spending and favorable reimbursement policies make advanced radiotherapy treatments more accessible and affordable for patients. For instance, Medicare is a public insurance program that covers most U.S. residents aged 65 or older, disabled individuals, and those with end-stage renal disease or ALS. It provides claims data for research purposes. Medicare Part A includes coverage for inpatient cancer treatments, while Part B covers outpatient services such as chemotherapy, radiation therapy, surgery, diagnostic tests, and durable medical equipment. On the other hand, the National Institutes of Health (NIH) has established the Cancer Screening Research Network (CSRN) to assess new cancer screening technologies, supporting the Biden-Harris administration's Cancer Moonshot initiative. Funded by the National Cancer Institute (NCI), eight groups will begin initial network activities. In 2024, the CSRN will launch the Vanguard Study on Multi-Cancer Detection (MCD) to test the feasibility of MCD blood tests in a pilot study involving up to 24,000 participants. The goal is to design a larger trial to determine if MCD tests can effectively reduce cancer deaths by detecting cancers earlier and evaluating their overall benefits versus harms. Such significant financial support from the government encourages the adoption of state-of-the-art radiotherapy technologies, thereby boosting market growth.

United States Radiotherapy Market Segmentation:

IMARC Group provides an analysis of the key trends in each segment of the market, along with forecasts at the country and regional levels for 2024-2032. Our report has categorized the market based on type, application, and end user.

Breakup by Type:

• External Beam Radiation Therapy
  • Intensity-Modulated Radiation Therapy (IMRT)
  • Image-Guided Radiation Therapy (IGRT)
  • Tomotherapy
  • Stereotactic Radiosurgery
  • Stereotactic Body Radiation Therapy
  • Proton Therapy
  • 3D Conformal Radiotherapy (3D CRT)
  • Volumetric Modulated Arc Therapy (VMAT)
• Internal Radiation Therapy/Brachytherapy
• Systemic Radiation Therapy
   

The report has provided a detailed breakup and analysis of the market based on the type. This includes external beam radiation therapy (intensity-modulated radiation therapy (IMRT), image-guided radiation therapy (IGRT), tomotherapy, Stereotactic radiosurgery, stereotactic body radiation therapy, proton therapy, 3D conformal radiotherapy (3D CRT), and volumetric modulated arc therapy (VMAT)), internal radiation therapy/brachytherapy, and systemic radiation therapy.

The United States radiotherapy market encompasses various advanced therapies. External Beam Radiation Therapy (EBRT) includes techniques like Intensity-Modulated Radiation Therapy (IMRT), which precisely targets cancer cells while sparing healthy tissues, and Image-Guided Radiation Therapy (IGRT), which enhances accuracy through real-time imaging. Tomotherapy combines CT imaging with radiation for continuous, precise treatment, particularly for complex cases. Stereotactic Radiosurgery and Stereotactic Body Radiation Therapy (SBRT) offer high precision and effectiveness in treating small and localized tumors, respectively. Proton Therapy is known for its precision, especially beneficial for pediatric cancers. 3D Conformal Radiotherapy shapes beams to tumor contours, and Volumetric Modulated Arc Therapy (VMAT) delivers quick, accurate radiation. Internal Radiation Therapy/Brachytherapy directly places radioactive sources near tumors, ideal for prostate and cervical cancers. Systemic Radiation Therapy uses radioactive substances to target widespread cancers, with advances in targeted drugs driving its growth.

Breakup by Application:

• Skin and Lip Cancer
• Head and Neck Cancer
• Breast Cancer
• Prostate Cancer
• Cervical Cancer
• Lung Cancer
• Others
   

A detailed breakup and analysis of the market based on the application have also been provided in the report. This includes skin and lip cancer, head and neck cancer, breast cancer, prostate cancer, cervical cancer, lung cancer, and others.

The rising prevalence of skin and lip cancers, driven by UV exposure and lifestyle factors, fuels demand for radiotherapy. Advanced techniques like intensity-modulated radiation therapy (IMRT) offer precise treatment. Head and neck cancers, often linked to smoking and alcohol, require effective treatments, with proton therapy and IMRT enhancing precision. Breast cancer, highly common among women, benefits from radiotherapy's effectiveness in reducing recurrence rates post-surgery, aided by technologies like image-guided radiotherapy (IGRT). According to American Cancer Society, breast cancer is the most common cancer among women in the U.S., accounting for 30% of new female cancers each year. In 2024, an estimated 310,720 new cases of invasive breast cancer and 56,500 cases of ductal carcinoma in situ (DCIS) will be diagnosed. Prostate cancer, prevalent in older men, sees demand for radiotherapy through advancements like brachytherapy. Cervical cancer in underserved populations necessitates comprehensive radiotherapy options like brachytherapy. Lung cancer's high mortality rate drives need for precise treatments like stereotactic body radiotherapy (SBRT). Radiotherapy also treats various other cancers, with specialized techniques improving outcomes.

Breakup by End User:

• Hospitals
• Cancer Research Institutes
• Ambulatory and Radiotherapy Centers
   

The report has provided a detailed breakup and analysis of the market based on the end user. This includes hospitals, cancer research institutes, and ambulatory and radiotherapy centers.

Hospitals drive the U.S. radiotherapy market by offering comprehensive cancer treatment with advanced technologies and multidisciplinary care, supported by substantial funding and infrastructure. Cancer research institutes contribute by pioneering innovative radiotherapy techniques through extensive clinical trials, research, and collaborations with technology firms, enhancing treatment efficacy and safety. Ambulatory and radiotherapy centers promote market growth by providing specialized, outpatient services that improve patient convenience and reduce costs, focusing on high-quality, targeted treatments with shorter durations and minimal hospital stays. Their streamlined operations and patient-centric approach make advanced radiotherapy more accessible, supporting market expansion.

Breakup by Region:

• Northeast
• Midwest
• South
• West
   

The report has also provided a comprehensive analysis of all the major regional markets, which include Northeast, Midwest, South, and West.

The Northeast benefits from advanced healthcare facilities and research institutions, fostering innovation in radiotherapy technologies. High cancer prevalence and robust funding make advanced treatments accessible. In the Midwest, increasing cancer rates and expanding healthcare infrastructure, including mobile units and telemedicine, drive demand. The South experiences rising radiotherapy demand due to higher cancer rates, improved facilities, and state-level support. The West emphasizes technological innovation and advanced infrastructure, with high cancer prevalence and significant healthcare investments enhancing access to cutting-edge treatment.

In 2023, U.S. healthcare spending is projected to have increased by 7.5% to $4.8 trillion, surpassing the projected annual GDP growth rate of 6.1%. This growth was primarily driven by increased spending on Medicaid and private health insurance. The insured share of the population reached a historic high of 93%, as reported by the U.S. Centers for Medicare and Medicaid Services (CMS).

Competitive Landscape:

• The market research report has also provided a comprehensive analysis of the competitive landscape. Competitive analysis such as market structure, key player positioning, top winning strategies, competitive dashboard, and company evaluation quadrant has been covered in the report. Also, detailed profiles of all major companies have been provided.
• The competitive landscape of the U.S. radiotherapy market is characterized by the presence of several key players that dominate the market through continuous innovation and advanced technological offerings such as proton therapy, stereotactic radiosurgery, and AI-driven treatment planning. Intense competition drives ongoing research and development, partnerships, and strategic acquisitions. Smaller firms and startups also contribute to the market by introducing niche technologies and specialized solutions. The competitive environment is further influenced by regulatory approvals, reimbursement policies, and the adoption of advanced radiotherapy systems by leading healthcare institutions, enhancing treatment precision and patient outcomes. Overall, the market is dynamic, with a focus on technological advancements and improved healthcare delivery.
• For instance, in May 2023, IntraOp Medical Corporation announced the world's first Phase II Electron FLASH Trial, which will compare FLASH radiotherapy to conventional radiotherapy for nonmelanoma skin cancer (NMSC) patients.
• In February 2023, RefleXion Medical received FDA clearance for its SCINTIX biology-guided radiotherapy, a groundbreaking treatment for early and late-stage cancers. SCINTIX uniquely allows each cancer's biology to autonomously guide radiation delivery in real-time. This innovation expands the RefleXion X1 platform, making it the only dual-modality system for treating solid tumors at any stage. The X1 also features an advanced anatomic modality cleared by the FDA for solid tumors.

United States Radiotherapy Market News:

• In July 2023, GE HealthCare, a global leader in medical technology, diagnostics, and digital solutions, announced the extension of its collaboration with Elekta, a radiation therapy leader. This partnership aims to expand access to precision radiation therapy by providing hospitals with a comprehensive range of imaging and treatment solutions for cancer patients requiring radiation therapy.
• In October 2023, Accuray Incorporated announced that China's National Medical Products Administration (NMPA) has approved the Tomo C radiation therapy system, developed through a joint venture with CNNC, for the Type B market. This approval marks a significant milestone as the first joint venture product made in China. The Tomo C system aims to enhance cancer treatment options for patients, many of whom will require radiotherapy for curing cancer, improving cure rates, or alleviating cancer-related symptoms.

United States Radiotherapy Market Report Scope:

Key Questions Answered in This Report:

• How has the United States radiotherapy market performed so far, and how will it perform in the coming years?
• What has been the impact of COVID-19 on the United States radiotherapy market?
• What is the breakup of the United States radiotherapy market on the basis of type?
• What is the breakup of the United States radiotherapy market on the basis of application?
• What is the breakup of the United States radiotherapy market on the basis of end user?
• What are the various stages in the value chain of the United States radiotherapy market?
• What are the key driving factors and challenges in the United States radiotherapy market?
• What is the structure of the United States radiotherapy market, and who are the key players?
• What is the degree of competition in the United States radiotherapy market?

Key Benefits for Stakeholders:

• IMARC’s industry report offers a comprehensive quantitative analysis of various market segments, historical and current market trends, market forecasts, and dynamics of the United States radiotherapy market from 2018-2032.
• The research report provides the latest information on the market drivers, challenges, and opportunities in the United States radiotherapy market.
• Porter's five forces analysis assists stakeholders in assessing the impact of new entrants, competitive rivalry, supplier power, buyer power, and the threat of substitution. It helps stakeholders to analyze the level of competition within the United States radiotherapy industry and its attractiveness.
• The competitive landscape allows stakeholders to understand their competitive environment and provides an insight into the current positions of key players in the market.